China SXT Pharmaceuticals, Inc. (SXTC) Net margin 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) net profit margin by fiscal year — reported net income divided by reported revenue.
-545.2%FY2026 · since FY2017: 24.3% → -545.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -545.2% | -355.5 pp |
| FY2025 | -189.8% | -29.1 pp |
| FY2024 | -160.7% | +140.3 pp |
| FY2023 | -301.0% | -80.6 pp |
| FY2022 | -220.4% | -162.9 pp |
| FY2021 | -57.5% | +141.8 pp |
| FY2020 | -199.3% | -221.2 pp |
| FY2019 | 22.0% | +5.0 pp |
| FY2018 | 16.9% | -7.4 pp |
| FY2017 | 24.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice